Tasos Konidaris - 01 Mar 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
Executive Vice President & CFO
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 15:30:26 UTC
Previous filing
15 Mar 2022
Next filing
07 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +36,197 +17% 247,832 01 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -36,197 -33% $0.000000 72,394 01 Mar 2023 Class A Common Stock 36,197 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 On March 1, 2021, the reporting person was granted 144,788 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

Exhibit 24-Power of Attorney